Recent patents on oral insulin

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 3, 2010, Pages 248-252

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Agrawal, Navneet ^b   Khare, Sandeep ^a  

^a India   (India)

^b G R MEDICAL COLLEGE   (India)

Author keywords

Delivery routes; Diabetes; Oral insulin

Indexed keywords

BACITRACIN; CAMOSTAT MESILATE; FATTY ACID SALT; GLUCOSE; GLYCOLATE SODIUM; GLYCOLIC ACID DERIVATIVE; IN 105; INSULIN; INSULIN DERIVATIVE; LIPOSOME; METFORMIN; MONOSODIUM N ( 4 CHLOROSALICYLOYL) 4 AMINO BUTYRIC ACID; NANOPARTICLE; PENETRATION ENHANCING AGENT; PLACEBO; POLYGLACTIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; ZONULA OCCLUDENS TOXIN;

ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG METABOLISM; DRUG PACKAGING; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NANOENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RABBIT; SIDE EFFECT; SINGLE DRUG DOSE; SKIN BRUISING; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 78649340484     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872214811004030248     Document Type: Article

References (37)

1. Mahler RJ, Adler ML. Type 2 diabetes mellitus: Update on diagnosis, pathophysiology and treatment. J Clin Endocrinol Metab 1999; 84: 1165-71.
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
3. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin? Diabetes Care 2005; 28: 78-83.
4. Vijan S, Hayward RA, Ronis DL, Hofer TP. The burden of diabetes therapy: Implications for the design of effective patient- centered treatment regimens. J Gen Intern Med 2005; 20: 479-82.
5. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: Patient and health care provider perspectives. Diabetes Educator 2009; 35: 1014-22.
6. Iyer H, Khedkar A, Verma M. Oral insulin - a review of current status. Diabetes Obes Metab 2010; 12(3): 179-85.
7. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010; 33 (2): 240-5.
8. Diabetes Attitudes and Wishes and Needs (DAWN) study, Barriers to treatment. Available at: http://www.dawnstudy.com/documents/article_page/document/barriers.asp (Accessed on September 1, 2010).
9. Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol Ther 2004; 6: 510-7.
10. Arbit, E., Dinh, S., Goldberg, M. Antidiabetic oral insulin- biguanide combination. US2010048454 (2010).
11. Arbit, E., Goldberg, M., Majuru, S. Oral insulin therapies and protocol. US2009318331 (2009).
12. Foeger, F. A. Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides. WO2010060667 (2010).
13. Wang W. Oral protein delivery. J Drug Target 1996; 4: 195-232.
14. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev 1999; 35: 249-57.
15. David, A. E., Yang, A. J., Park, Y. J., Chang, L.-C., Yang, V. C. Innovative formulation for oral insulin delivery. WO2009020577 (2009).
16. Sabetsky, V. Oral insulin composition and methods of making and using thereof. US2010167985 (2010).
17. Aspden TJ, Mason JD, Jones NS. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509-13.
18. Dapergolas G, Gregoriadis G. Hypoglycaemic effect of liposome- entrapped insulin administered intragastrically into rats. Lancet 1976; 2: 824-7.
19. Pappo J, Ermak TH. Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: A quantitative model for M cell uptake. Clin Exp Immunol 1989; 76: 144-8.
20. Yamamoto A, Taniguchi T, Rikyuu K, Tsuji T, Fujita T, Murakami M, et al. Effect of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm Res 1994; 11: 1496-500.
21. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: The glucose stabilization effects of HIM2. Diabetes Technol Ther 2002; 4: 459-66.
22. Fasano A, Uzzau S. Modulation of intestinal tight junctions zona occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997; 99: 1158-64.
23. Kaptiza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: A comparison with subcutaneous regular human insulin in patients with type 2. Diabetes Care 2010; 33(6): 1288-90.
24. Lowman AM, Morishita M, Kashita M, Nagai T, Peppas NA. Oral insulin of delivery using pH-sensitive complexation gels. J Pharm Sci 1999: 88 (9): 933-7.
25. th Scientific Sessions, Orlando, USA (2004).
26. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004; 53: 1614-20.
27. Madsen, P., Hoeg-Jensen, T., Kjeldsen, T. B., Tagmose, T. M. Protease stabilized, pegylated insulin analogues. EP2170945 (2010).
28. Mahkam M. Starch-based polymeric carriers for oral-insulin delivery. J Biomed Mater Res A 2010; 92(4): 1392-7.
29. Khedkar A, Iyer H, Anand A, Verma M, Krishnamurthy S, Savale S, et al. A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. Diabetes Obes Metab 2010; 12: 659-64.
30. th Scientific Sessions, San Diego, USA (2005).
31. Kogure, K., Watanabe, M., Harashima, H. Systems, devices, and methods for iontophoretic delivery of compositions including liposome-encapsulated insulin. US2009022784 (2009).
32. th Scientific Sessions, San Francisco, USA (2008).
33. Luzio S, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens D. Comparison of an oral insulin (Capsulin) and Actrapid during an isoglycemic clamp study in persons with type 2 diabetes. Diabetes 2008; 56(Suppl 1): A10
34. Phillips J, Russel-Jones DL, Wright J, Brackenridge A, New R, Bansal G. Early evaluation of a novel oral insulin delivery system in healthy volunteers. Diabetes 2004; 53(Suppl 2): A113.
35. th Scientific Sessions. San Francisco, USA (2008).
36. Palmqvist, E. M. A., Hubalek, F., Plum, A., Potshard, T., Haakansson-Hederos, S., Ribel-Madsen, U., Lautrup-Larsen, I. Insulin precursors for diabetes treatment. WO2009133099 (2009).
37. Pozzilli P, Raskin P, Parkin CG. Review of clinical trials: Update on oral insulin spray formulation. Diabetes Obes Metab 2010; 12: 91-96.